NLR family pyrin domain containing 1 (NLRP1) inflammasome complex (NLRP1)

The NLR family pyrin domain containing 1 (NLRP1) inflammasome complex is a multi-protein platform that plays a critical role in the innate immune system by sensing various pathogen-associated and danger-associated molecular patterns (UniProt Q9C000). Unlike other inflammasomes, NLRP1 is activated through a unique functional degradation mechanism, where the N-terminal portion of the protein is cleaved and degraded by the proteasome, releasing a bioactive C-terminal fragment (PubMed: 31006067). This fragment then recruits the adapter protein ASC and pro-caspase-1, leading to the maturation of pro-inflammatory cytokines IL-1β and IL-18 and the induction of pyroptotic cell death (PubMed: 33442717). NLRP1 is highly expressed in the skin and lungs, and its dysregulation is linked to several autoinflammatory diseases, including vitiligo, psoriasis, and NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis) (PubMed: 27525440). In the context of drug development, NLRP1 is a target for both inhibition in autoimmune conditions and activation in oncology, where DPP8/9 inhibitors like Talabostat have been shown to trigger NLRP1-dependent anti-tumor immunity (PubMed: 29551515).

Other names

NALP1CARD7DEFCAPNACSLEV1VPPNucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 1

The NLRP1 inflammasome is activated via a unique mechanism termed functional degradation, where N-terminal cleavage (triggered by viral proteases or DPP8/9 inhibition) leads to proteasomal degradation of the inhibitory N-terminal fragment, thereby releasing the bioactive C-terminal UPA-CARD fragment to recruit ASC and caspase-1 for cytokine maturation (PubMed: 31006067).